Table Graph
      published meta-analysis   sensitivity analysis   studies

Immunosuppressants drugs in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] CAN-COVID, 2020 0.67 [0.30; 1.50] CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19] CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] RECOVERY, 2022 0.87 [0.77; 0.98] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.59 [0.33; 1.06] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 0.76[0.65; 0.87]ACTT-2 (Kalil), 2020, CAN-COVID, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RECOVERY, 2022, Rosas (REMDACTA), 2021, Rutgers, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021, Talaschian, 2021, Veiga, 20212314%14,192moderatecritical death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] 0.97[0.50; 1.88]BACC Bay Tocilizumab Trial, 202010%242NAnot evaluable deathsdetailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] CAN-COVID, 2020 0.67 [0.30; 1.50] CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04] CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EMPACTA, 2020 1.13 [0.54; 2.40] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37] RECOVERY, 2021 0.85 [0.76; 0.95] RECOVERY, 2022 0.87 [0.77; 0.98] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.62 [0.36; 1.07] SAVE-MORE, 2021 0.45 [0.20; 0.99] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] 0.81[0.75; 0.88]ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EMPACTA, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, LIVE-AIR (Temesgen), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, RECOVERY, 2022, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021, Talaschian, 2021, Veiga, 2021344%21,700moderatecritical deaths (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] COV-BARRIER, 2021 0.57 [0.41; 0.79] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Rutgers, 2021 0.62 [0.36; 1.07] Talaschian, 2021 1.25 [0.30; 5.14] 0.76[0.60; 0.95]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, LIVE-AIR (Temesgen), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021734%4,523moderatenot evaluable clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92] CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] COV-BARRIER, 2021 1.12 [0.58; 2.16] EMPACTA, 2020 0.55 [0.33; 0.92] RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86] SAVE-MORE, 2021 0.36 [0.26; 0.50] Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77] STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07] 0.71[0.52; 0.98]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 20211061%2,457moderatecritical clinical improvementdetailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] CAN-COVID, 2020 1.39 [0.76; 2.54] COV-BARRIER, 2021 1.25 [1.04; 1.50] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Dongsheng Wang, 2020 2.37 [0.40; 13.96] EMPACTA, 2020 1.15 [0.90; 1.47] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.22[1.11; 1.34]ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021129%4,877lowlow clinical improvement (14-day)detailed resultsACTT-2 (Kalil), 2020 1.30 [1.03; 1.64] COV-BARRIER, 2021 1.28 [1.05; 1.56] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] 1.31[1.13; 1.52]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 202230%2,659lownot evaluable clinical improvement (28-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.33[0.95; 1.87]COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202140%564moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] EMPACTA, 2020 1.15 [0.90; 1.47] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] 1.14[1.03; 1.27]ACTT-2 (Kalil), 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202140%1,539lownot evaluable death or ventilationdetailed resultsACTT-2 (Kalil), 2020 0.69 [0.50; 0.95] BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52] CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] EMPACTA, 2020 0.56 [0.32; 0.97] LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] RECOVERY, 2021 0.85 [0.78; 0.93] RECOVERY, 2022 0.90 [0.81; 0.99] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] Rutgers, 2021 0.65 [0.43; 0.99] STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97] Veiga, 2021 1.54 [0.65; 3.63] 0.83[0.77; 0.91]ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, RECOVERY, 2021, RECOVERY, 2022, Rosas (REMDACTA), 2021, Rutgers, 2021, STOP-COVID (Guimarães), 2021, Veiga, 20211318%14,546moderatelow hospital dischargedetailed resultsEMPACTA, 2020 1.16 [0.90; 1.49] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] 1.05[0.88; 1.25]EMPACTA, 2020, Rosas (REMDACTA), 2021213%649moderatenot evaluable mechanical ventilationdetailed resultsACTT-2 (Kalil), 2020 0.64 [0.44; 0.93] COVACTA (Rosas), 2020 0.67 [0.39; 1.14] RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69] RECOVERY, 2022 0.87 [0.74; 1.02] Rutgers, 2021 0.65 [0.35; 1.24] SAVE-MORE, 2021 0.47 [0.03; 7.48] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38] 0.81[0.70; 0.93]ACTT-2 (Kalil), 2020, COVACTA (Rosas), 2020, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, Rutgers, 2021, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 202191%10,489moderatenot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] Rutgers, 2021 0.96 [0.55; 1.68] Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64] 0.85[0.49; 1.49]COVACTA (Rosas), 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021357%724moderatenot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] Talaschian, 2021 0.64 [0.14; 2.92] 1.30[0.64; 2.66]COV-BARRIER (critically ill), 2022, Talaschian, 202129%137lownot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] CAN-COVID, 2020 0.73 [0.45; 1.19] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Dongsheng Wang, 2020 0.91 [0.02; 47.31] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 0.94[0.78; 1.13]BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021100%2,682moderatecritical superinfectiondetailed resultsACTT-2 (Kalil), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]ACTT-2 (Kalil), 202010%1,033NAnot evaluable adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Dongsheng Wang, 2020 9.64 [2.76; 33.75] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87] Veiga, 2021 1.65 [0.81; 3.37] 1.32[0.92; 1.91]COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021957%1,981moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2025-03-09 03:33 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons